» Articles » PMID: 36339922

Relationships Between Histopathological Findings in the Liver and Prognosis in Patients With Biliary Atresia

Overview
Journal Clin Pathol
Publisher Sage Publications
Date 2022 Nov 7
PMID 36339922
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Biliary atresia (BA) is a progressive obstructive hepatic disease that requires early diagnosis and the prompt initiation of treatment. Although portoenterostomy (PES) is usually performed as the initial surgical procedure, the liver damage may subsequently progress, such that liver transplantation (LTx) may be required. In this study, we comprehensively evaluated the histopathology of liver samples collected during PES and retrospectively evaluated its relationship with prognosis.

Methods: Forty-seven patients with BA who underwent PES between 2002 and 2021 were included. Their biopsy samples were semi-quantitatively graded according to the severity of liver fibrosis, bile duct proliferation, cholestasis, ductal plate malformation, and inflammatory cell infiltration; and the expression of cluster of differentiation (CD)3, CD20, human leukocyte antigen II-DR, and α-smooth muscle actin (α-SMA). The relationships of each with the prevalence of survival with native liver (SNL) were evaluated to identify prognostic markers.

Results: The median postoperative duration of follow-up was 11.8 years (maximum, 18.0 years; minimum, 3.5 years). There were no deaths during this period, but LTx was performed in 31 patients and the final prevalence of SNL was 34.0% (16/47). There were negative correlations of liver fibrosis and α-SMA with SNL, and a positive correlation between CD20 and SNL. Multivariate analysis using a proportional hazards regression model showed that only CD20 expression was significant.

Conclusions: Comprehensive histopathological analysis of liver biopsy samples obtained at the time of PES showed a positive correlation between CD20 expression and SNL, suggesting that this may represent a useful prognostic marker.

Level Of Evidence: III.

Citing Articles

Impact of follow-up liver biopsy on long-term outcomes post-Kasai procedure in patients with biliary atresia.

Takase K, Ueno T, Matsumoto S, Uga N, Deguchi K, Nomura M Pediatr Surg Int. 2025; 41(1):88.

PMID: 40019581 PMC: 11870969. DOI: 10.1007/s00383-025-05979-y.


Expression of activin A in liver tissue and the outcome of patients with biliary atresia.

Dzepina P, Coric M, Kovacic Perica M, Anicic M, Grizelj R, Vukovic J Front Pediatr. 2024; 12:1457837.

PMID: 39618695 PMC: 11604446. DOI: 10.3389/fped.2024.1457837.

References
1.
Weerasooriya V, White F, Shepherd R . Hepatic fibrosis and survival in biliary atresia. J Pediatr. 2004; 144(1):123-5. DOI: 10.1016/j.jpeds.2003.09.042. View

2.
Kobayashi H, Puri P, OBriain D, Surana R, Miyano T . Hepatic overexpression of MHC class II antigens and macrophage-associated antigens (CD68) in patients with biliary atresia of poor prognosis. J Pediatr Surg. 1997; 32(4):590-3. DOI: 10.1016/s0022-3468(97)90714-4. View

3.
Lopez R, Ooi C, Krishnan U . Early and Peri-operative Prognostic Indicators in Infants Undergoing Hepatic Portoenterostomy for Biliary Atresia: a Review. Curr Gastroenterol Rep. 2017; 19(4):16. DOI: 10.1007/s11894-017-0555-z. View

4.
Suominen J, Lampela H, Heikkila P, Lohi J, Jalanko H, Pakarinen M . Myofibroblastic cell activation and neovascularization predict native liver survival and development of esophageal varices in biliary atresia. World J Gastroenterol. 2014; 20(12):3312-9. PMC: 3964401. DOI: 10.3748/wjg.v20.i12.3312. View

5.
El-Guindi M, Sira M, Sira A, Salem T, El-Abd O, Konsowa H . Design and validation of a diagnostic score for biliary atresia. J Hepatol. 2014; 61(1):116-23. DOI: 10.1016/j.jhep.2014.03.016. View